North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
SHA: 600812
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...